Self-guided Acceptance and Commitment Therapy-based Digital Smartphone Application for Management of Fibromyalgia
A legfontosabb adatok
- Ki végzi
- Fundació Sant Joan de Déu
- Hol
- Spanyolország2 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 360 fő, tervezett
- Kezdés
- 2024. jan. 1.
- Várható befejezés
- 2027. márc. 31.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Self-guided digital Acceptance and Commitment Therapy
- FM symptom tracking app (FM-ST)
- Treatment as Usual (TAU)
- A regiszteradat frissítve
- 2026. július 23.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with fibromyalgia who have a smartphone and understand Spanish well. It tests a self-guided therapy app called STANZA-Spain.
- Életkor
- 18 Years to 70 Years
- Nem
- All sexes can join. Men cannot join the blood marker part of the study.
- A betegség stádiuma
- Fibromyalgia diagnosed by the 2016 ACR criteria. A Fibromyalgia Impact Questionnaire Revised (FIQR) total score of 35-80 at the start.
- Korábbi kezelés
- People must be willing to keep their current pain treatment during the study. People who took part in another clinical trial in the previous 12 months cannot join.
A részvétel fő kizáró okai
- Problems with memory or thinking in the medical records
- Severe medical or mental illness, such as cancer, psychotic disorder or drug abuse
- Being at risk of suicide
- Being pregnant, planning a pregnancy during the study, or breastfeeding
- Taking part in other clinical trials, or being unable to use a smartphone
A regiszter feltételei, szó szerint
Mind a 22 feltétel megnézéseKevesebb
Ki vehet részt
- Fibromyalgia diagnosis according to the 2016 ACR criteria
- Fibromyalgia Impact Questionnaire Revised (FIQR) total score within the range of 35-80 at baseline
- Willing to maintain their current pain treatment throughout the study
- Having a smartphone (iOS 12 or higher or Android OS 8 or higher)
- Proficient understanding of Spanish
Ki nem vehet részt
- Participation in other clinical trials during the study or within the previous 12 months
- Current use of oral or topical corticosteroids
- Current use of anti-cytokine biologic medications
- Presence of cognitive impairment according to clinical records
- Diagnosis of severe medical or mental disorders such as cancer, psychotic disorder, and drug abuse according to medical records
- Comorbid rheumatologic disorders such as lupus or severe organ dysfunction
- History of fever (> 38ºC) or infection within the last 2 weeks
- Patients at risk of suicide
- Being pregnant or planning a pregnancy during the study period, or currently breastfeeding
- Unable to use a smartphone
- Male sex
- Vaccination within the last 4 weeks
- Recent physical trauma
- Needle phobia
- Consumption of more than 8 units of caffeine per day
- Smoking more than 5 cigarettes per day
- Current use of oral contraceptives
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 70 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Spanyolország.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Introduction: Fibromyalgia (FM) is a prevalent syndrome that lacks curative treatment, imposing high healthcare and societal costs. The SMART-FM-Spain study investigates the effectiveness, physiological effects, and cost-utility of a self-guided digital intervention (STANZA-Spain) based on Acceptance and Commitment Therapy (ACT) for patients with FM.
A teljes eredeti leírásKevesebb
Methodology: Six-month, 3-arm randomized controlled trial (RCT) A total of 360 adult individuals meeting the 2016 American College of Rheumatology (ACR) criteria for FM will be recruited at Vall d'Hebron University Hospital (Barcelona, Spain), The Rheumatology Service of the Parc Sanitari Sant Joan de Déu (Sant Boi, Spain), The San Juan de Dios Hospital of Palma (Palma de Mallorca, Spain) and The San Juan de Dios Hospital of Aljarafe (Sevilla, Spain). They will be randomly allocated to one of the three study arms: Treatment as usual (TAU) plus STANZA-Spain, TAU plus digital symptom tracking (FibroST), or TAU. Participants will be assessed at baseline, post-treatment, and 6 month-follow-up. The primary outcome will be functional impairment, as measured by the FIQR; secondary outcomes will include patient impression of change, depression-anxiety-stress, and pain catastrophizing, among others constructs relevant to FM. Effectiveness and cost-utility analysis from a societal perspective will be computed, whereas ACT-related constructs, such as psychological flexibility, will be assessed to identify processes of change that will be analyzed with path analyses. Immune-inflamatory biomarkers will be assessed at baseline and post-treatment in 30-40 participants of each study arm. Additionally, a qualitative substudy using focus group thematic analysis will be conducted to deepen the understanding of STANZA app user experiences.
Discussion: This study might represent a significant advancement in the management of FM in Spanish-speaking patients with FM, by examining the effectiveness, physiological effects, and cost-utility of a smartphone-based digital therapeutic with demonstrated empirical support in the United States of America.
A vizsgálat 3 csoportja
- STANZA-SpainA vizsgált kezelés
Digital Acceptance and Commitment Terapy (ACT). It consists of 41 structured ACT lessons, incorporating mindfulness practices and daily activities to facilitate behavior change and promote gradual pacing of daily activities and exercise. The core content was designed to be completed within 8 weeks, with a 4-week maintenance period thereafter to strengthen skills.
Kezelés: Self-guided digital Acceptance and Commitment Therapy és Treatment as Usual (TAU)
- FibroST-SpainMár használt kezelés, összehasonlításként
A digital active control intervention is implemented to control for study engagement, expectations, and healthcare provider interaction biases. Components of this active comparator include daily symptom and function tracking (Daily Symptom Tracker), symptom and function monitoring, and access to health education articles about fibromyalgia.
Kezelés: FM symptom tracking app (FM-ST) és Treatment as Usual (TAU)
- Treatment as Usual (TAU)Már használt kezelés, összehasonlításként
Usual care is mainly carried out by general practitioners and rheumatologists through regular consultations. Clinicians prescribe medications and provide some counselling.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Three-arm Randomized Controlled Trial Investigating the Effectiveness, Cost-utility, and Physiological Effects of the Spanish Version of STANZA®: A Self-guided Digital Acceptance and Commitment Therapy (ACT) for Fibromyalgia
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT05962437: ki vehet részt
- A regiszteradat frissítve
- 2026. július 23.